DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767

European Journal of Cancer

Volumn 38, Issue 11, 2002, Pages 1543-1552

  Monks, Noel R ^a   Blakey, David C ^b   East, Simon J ^b   Dowell, Robert I ^b   Calvete, Joanne A ^a   Curtin, Nicola J ^a   Arris, Christine E ^a   Newell, David R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

ADEPT; Alkylating agent; DNA cross linking; Sensitivity; TP53; ZD2767

Indexed keywords

4 [N,N BIS(2 IODOETHYL)AMINO]PHENOL; 4 [N,N BIS(2 IODOETHYL)AMINO]PHENOXYCARBONYLGLUTAMIC ACID; CARBOXYPEPTIDASE G2; CHLORAMBUCIL; PROTEIN P53; UNCLASSIFIED DRUG; ZD 2767D; ZD 2767P;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; COLORECTAL TUMOR; CONTROLLED STUDY; DNA CROSS LINKING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR CELL;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; COLORECTAL NEOPLASMS; CROSS-LINKING REAGENTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GAMMA-GLUTAMYL HYDROLASE; HUMANS; LUNG NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036313592     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00111-9     Document Type: Article

References (30)

1. Trends in drug targeting for cancer
2. Novel therapeutic strategies to selectively kill cancer cells
3. Antibody directed enzymes revive anti-cancer prodrugs concept
4. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)
5. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts
6. Antibody-directed enzyme prodrug therapy (ADEPT): A review
7. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies
8. Molecular mechanisms of drug resistance
9. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies
10. CEA-related antigens: Molecular biology and clinical significance
11. Clinical applications of carcinoembryonic antigen
12. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard
13. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid
14. Inter-strand crosslinking of DNA by nitrogen mustard
15. Transcription-terminating lesions induced by bifunctional alkylating agents in vitro
16. Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
17. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
18. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16
19. New colorimetric cytotoxicity assay for anticancer-drug screening
20. Measurement of strand breaks and cross-links by alkaline elution
21. Towards generating cytotoxic agents at cancer sites
22. 16 melanoma cells
23. Cytotoxicity and sister chromatin exchanges in 9L cells treated with monofunctional and bifunctional nitrogen mustards
24. Evidence for the inactivation and repair of the mammalian DNA template after alkylation by mustard gas and half mustard gas
25. L-Phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line
26. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells
27. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs
28. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity
29. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation
30. Apoptosis induced by VP-16 independent of p53 and its mechanism in human colon cancer cell lines